Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00698035 · OUTCOME

Serum Estradiol (E2)

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients · Source last updated 2014-06-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
pg/ml
Interval / dispersion
Standard Deviation
Time frame
12 weeks

What was measured

serial measurements of serum estradiol (E2) by liquid chromatography tandem mass spectrometry (Quest Diagnostics)

Analysis population: Per protocol, participants who completed 12 weeks of assigned treatment

Groups in this outcome

Estring

Estring 2mg ring inserted vaginally once every 12 weeks

Testosterone Cream

Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Estring35
Testosterone Cream34

Reported measurements

E2 at baseline
Values in pg/ml · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Estring2736Not reportedNot reportedNot reported
Testosterone Cream913Not reportedNot reportedNot reported
E2 at 4 weeks
Values in pg/ml · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Estring55Not reportedNot reportedNot reported
Testosterone Cream1020Not reportedNot reportedNot reported
E2 at 12 weeks
Values in pg/ml · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Estring912Not reportedNot reportedNot reported
Testosterone Cream87Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        36
        value
        27
      2. group Id
        OG001
        spread
        13
        value
        9
    title
    E2 at baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        5
        value
        5
      2. group Id
        OG001
        spread
        20
        value
        10
    title
    E2 at 4 weeks
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        12
        value
        9
      2. group Id
        OG001
        spread
        7
        value
        8
    title
    E2 at 12 weeks
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    2. group Id
      OG001
      value
      34
    units
    Participants
description
serial measurements of serum estradiol (E2) by liquid chromatography tandem mass spectrometry (Quest Diagnostics)
dispersion Type
Standard Deviation
groups
  1. description
    Estring 2mg ring inserted vaginally once every 12 weeks
    id
    OG000
    title
    Estring
  2. description
    Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
    id
    OG001
    title
    Testosterone Cream
param Type
MEAN
population Description
Per protocol, participants who completed 12 weeks of assigned treatment
reporting Status
POSTED
time Frame
12 weeks
title
Serum Estradiol (E2)
type
SECONDARY
unit Of Measure
pg/ml

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice